A Novel Small Molecule Compound VCP979 Improves Ventricular Remodeling in Murine Models of Myocardial Ischemia/reperfusion Injury

Overview

Journal Int J Mol Med

Specialty Genetics

Date 2019 Dec 3

PMID 31789413

Citations 4

Authors

Jing Liu

Qingshu Meng

Xiaoting Liang

Rulin Zhuang

Dongsheng Yuan

Xinyu Ge

Hao Cao

Fang Lin

Xin Gong

Huimin Fan

Binghui Wang

Xiaohui Zhou

Zhongmin Liu

Affiliations

Soon will be listed here.

Abstract

Persistent ventricular remodeling following myocardial ischemia/reperfusion (MI/R) injury results in functional decompensation and eventual progression to heart failure. VCP979, a novel small‑molecule compound developed in‑house, possesses anti‑inflammatory and anti‑fibrotic activities. In the present study, no significant pathological effect was observed following the administration of VCP979 on multiple organs in mice and no difference of aspartate transaminase/alanine aminotransferase/lactate dehydrogenase levels was found in murine serum. Treatment with VCP979 ameliorated cardiac dysfunction, pathological myocardial fibrosis and hypertrophy in murine MI/R injury models. The administration of VCP979 also inhibited the infiltration of inflammatory cells and the pro‑inflammatory cytokine expression in hearts post MI/R injury. Further results revealed that the addition of VCP979 prevented the primary neonatal cardiac fibroblasts (NCFs) from Angiotensin II (Ang II)‑induced collagen synthesis and neonatal cardiac myocytes (NCMs) hypertrophy. In addition, VCP979 attenuated the activation of p38‑mitogen‑activated protein kinase in both Ang II‑induced NCFs and hearts subjected to MI/R injury. These findings indicated that the novel small‑molecule compound VCP979 can improve ventricular remodeling in murine hearts against MI/R injury, suggesting its potential therapeutic function in patients subjected to MI/R injury.

Citing Articles

Novel small-molecule compound VCP979 attenuates renal fibrosis in male rats with unilateral ureteral obstruction.

Min S, Chang D, Wang Y, Xu T, Ge H, Zhang J Exp Biol Med (Maywood). 2023; 248(4):327-338.

PMID: 36715096 PMC: 10159523. DOI: 10.1177/15353702221147569.

Reducing White Adipose Tissue Browning Using p38α MAPK Inhibitors Ameliorates Cancer-Associated Cachexia as Assessed by Magnetic Resonance Imaging.

Zhao Y, Dai J, Jiang Y, Wu H, Cui Y, Li X Nutrients. 2022; 14(15).

PMID: 35893867 PMC: 9331061. DOI: 10.3390/nu14153013.

Intramyocardial injected human umbilical cord-derived mesenchymal stem cells (HucMSCs) contribute to the recovery of cardiac function and the migration of CD4 T cells into the infarcted heart via CCL5/CCR5 signaling.

Liu J, Liang X, Li M, Lin F, Ma X, Xin Y Stem Cell Res Ther. 2022; 13(1):247.

PMID: 35690805 PMC: 9188247. DOI: 10.1186/s13287-022-02914-z.

Propionate alleviates myocardial ischemia-reperfusion injury aggravated by Angiotensin II dependent on caveolin-1/ACE2 axis through GPR41.

Deng F, Zhang L, Wu H, Chen Y, Yu W, Han R Int J Biol Sci. 2022; 18(2):858-872.

PMID: 35002530 PMC: 8741842. DOI: 10.7150/ijbs.67724.

References

Boag S, Andreano E, Spyridopoulos I . Lymphocyte Communication in Myocardial Ischemia/Reperfusion Injury. Antioxid Redox Signal. 2016; 26(12):660-675. DOI: 10.1089/ars.2016.6940. View

Shinde A, Frangogiannis N . Fibroblasts in myocardial infarction: a role in inflammation and repair. J Mol Cell Cardiol. 2013; 70:74-82. PMC: 3995820. DOI: 10.1016/j.yjmcc.2013.11.015. View

Iwata M, Cowling R, Yeo S, Greenberg B . Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. J Mol Cell Cardiol. 2010; 51(4):542-7. PMC: 3085048. DOI: 10.1016/j.yjmcc.2010.12.003. View

Lemke L, Bloem L, Fouts R, Esterman M, Sandusky G, Vlahos C . Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart. J Mol Cell Cardiol. 2001; 33(8):1527-40. DOI: 10.1006/jmcc.2001.1415. View

Kompa A, See F, Lewis D, Adrahtas A, Cantwell D, Wang B . Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction. J Pharmacol Exp Ther. 2008; 325(3):741-50. DOI: 10.1124/jpet.107.133546. View

Xu T, Ding J, Ge H, Xu X, Scammells P, Wang B . Effects of VCP979 Novel p38 Mitogen Activated Protein Kinase Inhibitor on Progression of Pancreatic Cancer in Mouse Model with Diabetic Conditions. J Biomed Nanotechnol. 2019; 15(6):1325-1333. DOI: 10.1166/jbn.2019.2775. View

Iwata M, Cowling R, Gurantz D, Moore C, Zhang S, Yuan J . Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol. 2005; 289(6):H2356-63. DOI: 10.1152/ajpheart.00317.2005. View

Krum H, Teerlink J . Medical therapy for chronic heart failure. Lancet. 2011; 378(9792):713-21. DOI: 10.1016/S0140-6736(11)61038-6. View

Tamargo J, Caballero R, Delpon E . New drugs in preclinical and early stage clinical development in the treatment of heart failure. Expert Opin Investig Drugs. 2018; 28(1):51-71. DOI: 10.1080/13543784.2019.1551357. View

10.

Moran A, Forouzanfar M, Roth G, Mensah G, Ezzati M, Flaxman A . The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation. 2014; 129(14):1493-501. PMC: 4181601. DOI: 10.1161/CIRCULATIONAHA.113.004046. View

11.

Zhang X, Wang Y, Shen W, Ma S, Chen W, Qi R . Rosa rugosa flavonoids alleviate myocardial ischemia reperfusion injury in mice by suppressing JNK and p38 MAPK. Microcirculation. 2017; 24(7). DOI: 10.1111/micc.12385. View

12.

Stabile E, Kinnaird T, la Sala A, Hanson S, Watkins C, Campia U . CD8+ T lymphocytes regulate the arteriogenic response to ischemia by infiltrating the site of collateral vessel development and recruiting CD4+ mononuclear cells through the expression of interleukin-16. Circulation. 2005; 113(1):118-24. DOI: 10.1161/CIRCULATIONAHA.105.576702. View

13.

Ma Y, Hu Y, Wu J, Wen J, Li S, Zhang L . Epigallocatechin-3-gallate inhibits angiotensin II-induced cardiomyocyte hypertrophy via regulating Hippo signaling pathway in H9c2 rat cardiomyocytes. Acta Biochim Biophys Sin (Shanghai). 2019; 51(4):422-430. DOI: 10.1093/abbs/gmz018. View

14.

Eltzschig H, Eckle T . Ischemia and reperfusion--from mechanism to translation. Nat Med. 2011; 17(11):1391-401. PMC: 3886192. DOI: 10.1038/nm.2507. View

15.

Prabhu S . It takes two to tango: monocyte and macrophage duality in the infarcted heart. Circ Res. 2014; 114(10):1558-60. PMC: 4039188. DOI: 10.1161/CIRCRESAHA.114.303933. View

16.

Dolber P, Beyer E, Junker J, SPACH M . Distribution of gap junctions in dog and rat ventricle studied with a double-label technique. J Mol Cell Cardiol. 1992; 24(12):1443-57. DOI: 10.1016/0022-2828(92)91085-j. View

17.

Du M, Huang K, Gao L, Yang L, Wang W, Wang B . Nardosinone protects H9c2 cardiac cells from angiotensin II-induced hypertrophy. J Huazhong Univ Sci Technolog Med Sci. 2013; 33(6):822-826. DOI: 10.1007/s11596-013-1205-9. View

18.

Arkin M, Wells J . Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 2004; 3(4):301-17. DOI: 10.1038/nrd1343. View

19.

Frangogiannis N, Mendoza L, Lindsey M, Ballantyne C, Michael L, Smith C . IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J Immunol. 2000; 165(5):2798-808. DOI: 10.4049/jimmunol.165.5.2798. View

20.

Basu R, Poglitsch M, Yogasundaram H, Thomas J, Rowe B, Oudit G . Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. J Am Coll Cardiol. 2017; 69(7):805-819. DOI: 10.1016/j.jacc.2016.11.064. View